Profound Medical Corp. reported a notable 50.7% increase in revenue for fiscal 2025, reaching $16.1 million, driven by growing clinical traction of its TULSA-PRO system and new product launches. Despite this top-line momentum, operating losses deepened by nearly 25%, with net losses widening by 53% to $42.6 million, reflecting intensified investment in R&D and commercialization efforts. The firm's liquidity remains robust with a current ratio above 12 and nearly $60 million in cash reserves, providing a buffer amid ongoing negative operating cash flows. Capital allocation has focused on sustaining innovation and clinical expansions without dividends or share repurchases. The near-term growth outlook hinges on successful clinical validation and market adoption, though risks around financial sustainability persist given limited disclosure on intellectual property and regulatory status.